Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Optimization and Characterization of Aqueous Micellar Formulations for Ocular Delivery of an Antifungal Drug, Posaconazole

Author(s): Meltem E. Durgun, Emine Kahraman, Sevgi Güngör* and Yıldız Özsoy

Volume 26, Issue 14, 2020

Page: [1543 - 1555] Pages: 13

DOI: 10.2174/1381612826666200313172207

Price: $65

conference banner
Abstract

Background: Topical therapy is preferred for the management of ocular fungal infections due to its superiorities which include overcoming potential systemic side effects risk of drugs, and targeting of drugs to the site of disease. However, the optimization of effective ocular formulations has always been a major challenge due to restrictions of ocular barriers and physiological conditions. Posaconazole, an antifungal and highly lipophilic agent with broad-spectrum, has been used topically as off-label in the treatment of ocular fungal infections due to its highly lipophilic character. Micellar carriers have the potential to improve the solubility of lipophilic drugs and, overcome ocular barriers.

Objective: In the current study, it was aimed optimization of posaconazole loaded micellar formulations to improve aqueous solubility of posaconazole and to characterize the formulations and to investigate the physical stability of these formulations at room temperature (25°C, 60% RH), and accelerated stability (40°C, 75% RH) conditions.

Methods: Micelles were prepared using a thin-film hydration method. Pre-formulation studies were firstly performed to optimize polymer/surfactant type and to determine their concentration in the formulations. Then, particle size, size distribution, and zeta potential of the micellar formulations were measured by ZetaSizer Nano-ZS. The drug encapsulation efficiency of the micelles was quantified by HPLC. The morphology of the micelles was depicted by AFM. The stability of optimized micelles was evaluated in terms of particle size, size distribution, zeta potential, drug amount and pH for 180 days. In vitro release studies were performed using Franz diffusion cells.

Results: Pre-formulation studies indicated that single D-ɑ-tocopheryl polyethylene glycol succinate (TPGS), a combination of it and Pluronic F127/Pluronic F68 are capable of formation of posaconazole loaded micelles at specific concentrations. Optimized micelles with high encapsulation efficiency were less than 20 nm, approximately neutral, stable, and in aspherical shape. Additionally, in vitro release data showed that the release of posaconazole from the micelles was higher than that of suspension.

Conclusion: The results revealed that the optimized micellar formulation of posaconazole offers a potential approach for topical ocular administration.

Keywords: Micelles, D-ɑ-tocopheryl polyethylene glycol succinate (TPGS), Pluronic F127, Pluronic F68, posaconazole, antifungal agent, ocular drug delivery, antifungal therapy.

« Previous Next »
[1]
DeCroos FC, Garg P, Reddy AK, et al. Optimizing diagnosis and management of nocardia keratitis, scleritis, and endophthalmitis: 11-year microbial and clinical overview. Ophthalmology 2011; 118(6): 1193-200.
[http://dx.doi.org/10.1016/j.ophtha.2010.10.037] [PMID: 21276615]
[2]
The DrugBank [homepage on the Internet]. [cited 2019 Nov 04]. Available from:. www.drugbank.ca/drugs/DB01263
[3]
Beardsley RM, Suhler EB, Rosenbaum JT, Lin P. Pharmacotherapy Of Scleritis: Current Paradigms and Future Directions. Expert OpinPharmacother 2103; 14(4): 411-24.
[4]
Rupenthal ID, Alany RG. Ocular Drug deliveryOcular Drug Delivery- Pharmaceutical Manufacturing Handbook: Production And Processes. New Jersey: John Wiley & Sons, Inc 2008; pp. 729-68.
[http://dx.doi.org/10.1002/9780470259818.ch19]
[5]
Gaudana R, Jwala J, Boddu SHS, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res 2009; 26(5): 1197-216.
[http://dx.doi.org/10.1007/s11095-008-9694-0] [PMID: 18758924]
[6]
Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Nanocarriers in ocular drug delivery: an update review. Curr Pharm Des 2009; 15(23): 2724-50.
[http://dx.doi.org/10.2174/138161209788923886] [PMID: 19689343]
[7]
Cho HK, Cheong IW, Lee JM, Kim JH. Polymeric Nanoparticles, Micelles AndPolymersomes From Amphiphilic Block Copolymer. Korean J Chem Eng 2010; 27(3): 731-40.
[http://dx.doi.org/10.1007/s11814-010-0216-5]
[8]
Pepić I, Hafner A, Lovrić J, Pirkić B, Filipović-Grcić J. A nonionic surfactant/chitosan micelle system in an innovative eye drop formulation. J Pharm Sci 2010; 99(10): 4317-25.
[http://dx.doi.org/10.1002/jps.22137] [PMID: 20310026]
[9]
Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 2001; 73(2-3): 137-72.
[http://dx.doi.org/10.1016/S0168-3659(01)00299-1] [PMID: 11516494]
[10]
Nehoff H, Parayath NN, Domanovitch L, Taurin S, Greish K. Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. Int J Nanomedicine 2014; 9(1): 2539-55.
[PMID: 24904213]
[11]
Grimaudo MA, Pescina S, Padula C, et al. Poloxamer 407/TPGS Mixed Micelles as Promising Carriers for Cyclosporine Ocular Delivery. Mol Pharm 2018; 15(2): 571-84.
[http://dx.doi.org/10.1021/acs.molpharmaceut.7b00939] [PMID: 29313693]
[12]
Di Tommaso C, Bourges JL, Valamanesh F, et al. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies. Eur J Pharm Biopharm 2012; 81(2): 257-64.
[http://dx.doi.org/10.1016/j.ejpb.2012.02.014] [PMID: 22445900]
[13]
Sun F, Zheng Z, Lan J, et al. New micelle myricetin formulation for ocular delivery: improved stability, solubility, and ocular anti-inflammatory treatment. Drug Deliv 2019; 26(1): 575-85.
[http://dx.doi.org/10.1080/10717544.2019.1622608] [PMID: 31172843]
[14]
Mandal A, Bisht R, Rupenthal ID, Mitra AK. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies. J Control Release 2017; 248: 96-116.
[http://dx.doi.org/10.1016/j.jconrel.2017.01.012] [PMID: 28087407]
[15]
Jaiswal M, Kumar M, Pathak K. Zero order delivery of itraconazole via polymeric micelles incorporated in situ ocular gel for the management of fungal keratitis. Colloids Surf B Biointerfaces 2015; 130: 23-30.
[http://dx.doi.org/10.1016/j.colsurfb.2015.03.059] [PMID: 25889081]
[16]
Younes NF, Abdel-Halim SA, Elassasy AI. Solutol HS15 based binary mixed micelles with penetration enhancers for augmented corneal delivery of sertaconazole nitrate: optimization, in vitro, ex vivo and in vivo characterization. Drug Deliv 2018; 25(1): 1706-17.
[http://dx.doi.org/10.1080/10717544.2018.1497107] [PMID: 30442039]
[17]
Sponsel WE, Graybill JR, Nevarez HL, Dang D. Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol 2002; 86(7): 829-30.
[http://dx.doi.org/10.1136/bjo.86.7.829-a] [PMID: 12084760]
[18]
Amiel H, Chohan AB, Snibson GR, Vajpayee R. Atypical fungal sclerokeratitis. Cornea 2008; 27(3): 382-3.
[http://dx.doi.org/10.1097/ICO.0b013e31815e9298] [PMID: 18362676]
[19]
Mourya VK, Inamdar N, Nawale RB, Kulthe SS. Polymeric micelles: general considerations and their applications. Ind J Pharm Educat Res 2011; 45(2): 128-38.
[20]
Gibson M. Ophthalmic Dosage FormsPharmaceutical Pre-formulation and Formulation. Florida: Interpharm/CRC 2004; pp. 459-90.
[21]
Wen SN, Chu CH, Wang YC, et al. Polymer-stabilized micelles reduce the drug rapid clearance in vivo. Journal of Nanomaterials Volume 2018; Article ID 5818592.
[http://dx.doi.org/10.1155/2018/5818592]
[22]
Trivedi R, Kompella UB. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond) 2010; 5(3): 485-505.
[http://dx.doi.org/10.2217/nnm.10.10] [PMID: 20394539]
[23]
Kahraman E, Karagöz E, Dinçer S, and Ozsoy Y. Polyethylenimine Modified and Non-Modified Polymeric Micelles Used for Nasal Administration of Carvedilol. J Biomed Nanotechnol 2015; 11(5): 890-9.
[http://dx.doi.org/10.1166/jbn.2015.1915] [PMID: 26349400]
[24]
Bahadori F, Kocyigit A, Onyuksel H, Dag A, Topcu G. Cytotoxic, Apoptotic and Genotoxic Effects of Lipid-Based and Polymeric Nano Micelles, an In Vitro Evaluation. Toxics 2017; 6(1) E7
[http://dx.doi.org/10.3390/toxics6010007] [PMID: 29301191]
[25]
Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet 2010; 49(6): 379-96.
[http://dx.doi.org/10.2165/11319340-000000000-00000] [PMID: 20481649]
[26]
Kujawski J, Czaja K, Dettlaff K, Żwawiak J. Ratajczak T ve Bernard MK. Structural and spectroscopic properties of posaconazole – Experimental and theoretical studies. J Mol Struct 2019; 1181: 179-89.
[http://dx.doi.org/10.1016/j.molstruc.2018.12.074]
[27]
Kulthe SS, Choudhari YM, Inamdar NN, Mourya V. Polymeric micelles: authoritative aspects for drug delivery. Des Monomers Polym 2012; 15(5): 465-521.
[http://dx.doi.org/10.1080/1385772X.2012.688328]
[28]
Hansson P, Lindman B. Surfactant-Polymer Interactions. Curr Opin Colloid Interface Sci 1996; 1: 604-13.
[http://dx.doi.org/10.1016/S1359-0294(96)80098-7]
[29]
Kahraman E, Özhan G, Özsoy Y, Güngör S. Polymeric micellar nanocarriers of benzoyl peroxide as potential follicular targeting approach for acne treatment. Colloids Surf B Biointerfaces 2016; 146: 692-9.
[http://dx.doi.org/10.1016/j.colsurfb.2016.07.029] [PMID: 27434156]
[30]
Kahraman E, Neşetoğlu N, Güngör S, Ünal DŞ, Özsoy Y. The combination of nanomicelles with terpenes for enhancement of skin drug delivery. Int J Pharm 2018; 551(1-2): 133-40.
[http://dx.doi.org/10.1016/j.ijpharm.2018.08.053] [PMID: 30171899]
[31]
Taşcıoğlu S. Nanofiltration Mediated by Surfactant Micelles: Micellar- Enhanced Ultrafiltration. IntechOpen Limited. Farrukh, MA 2018; pp. 85-117.
[32]
Suksiriworapong J, Mingkwan T, Chantasart D. Enhanced transmucosal delivery of itraconazole by thiolated d-ɑ-tocopheryl poly(ethylene glycol) 1000 succinate micelles for the treatment of Candida albicans. Eur J Pharm Biopharm 2017; 120: 107-15.
[http://dx.doi.org/10.1016/j.ejpb.2017.08.012] [PMID: 28865759]
[33]
Eaton P, Quaresma P, Soares C, et al. A direct comparison of experimental methods to measure dimensions of synthetic nanoparticles. Ultramicroscopy 2017; 182: 179-90.
[http://dx.doi.org/10.1016/j.ultramic.2017.07.001] [PMID: 28692935]
[34]
Diebold Y, Calonge M. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 2010; 29(6): 596-609.
[http://dx.doi.org/10.1016/j.preteyeres.2010.08.002] [PMID: 20826225]
[35]
Danaei M, Dehghankhold M, Ataei S, et al. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics 2018; 10(2) E57
[http://dx.doi.org/10.3390/pharmaceutics10020057] [PMID: 29783687]
[36]
Bhattacharjee S. DLS and zeta potential - What they are and what they are not? J Control Release 2016; 235: 337-51.
[http://dx.doi.org/10.1016/j.jconrel.2016.06.017] [PMID: 27297779]
[37]
Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems - A review (Part 1). Trop J Pharm Res 2013; 12(2): 255-64.
[38]
World Health Organization [homepage on the Internet] [updated 2019; cited 2019 Nov 04]. Available from:. https://www.who.int/medicines/areas/quality_safety/quality_assurance/GuidelinesPackagingPharmaceuticalProductsTRS902Annex9.pdf?ua=1
[39]
Attar M, Brassard JA, Kim AS, Matsumoto S, Meg R, Vangyi C. Safety Evaluation of Ocular DrugsA Comprehensive Guide to Toxicology in Preclinical Drug Development. Detroit: Elsevier Inc 2013; pp. 567-617.
[http://dx.doi.org/10.1016/B978-0-12-387815-1.00024-1]
[40]
Bachu RD, Chowdhury P, Al-Saedi ZHF, Karla PK, Boddu SHS. Ocular Drug Delivery Barriers-Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases. Pharmaceutics 2018; 10(1) E28
[http://dx.doi.org/10.3390/pharmaceutics10010028] [PMID: 29495528]
[41]
Bennett L. Topical Versus Systemic Ocular Drug DeliveryOcular drug delivery: advances, challenges and applications. Cham: Springer Nature 2016; pp. 53-74.
[http://dx.doi.org/10.1007/978-3-319-47691-9_5]
[42]
Gouda R, Baishya H, Qing Z. Application of Mathematical Models in Drug Release Kinetics of Carbidopa and Levodopa ER Tablets. J Dev Drugs 2017; 6(2) 1000171
[43]
Andes D. Optimizing antifungal choice and administration. Curr Med Res Opin 2013; 29(Suppl. 4): 13-8.
[http://dx.doi.org/10.1185/03007995.2012.761135] [PMID: 23621589]
[44]
Yu Y, Chen D, Li Y, Yang W, Tu J, Shen Y. Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: formulation, in vitro and in vivo studies. Drug Deliv 2018; 25(1): 888-99.
[http://dx.doi.org/10.1080/10717544.2018.1458923] [PMID: 29631468]

Rights & Permissions Print Cite
Article Metrics
10
© 2024 Bentham Science Publishers | Privacy Policy